Suraj Kalia
Stock Analyst at Oppenheimer
(3.17)
# 1,091
Out of 4,784 analysts
85
Total ratings
40.58%
Success rate
3.31%
Average return
Main Sectors:
Stocks Rated by Suraj Kalia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATRC AtriCure | Maintains: Outperform | $36 → $45 | $31.83 | +41.38% | 7 | Feb 13, 2025 | |
| VREX Varex Imaging | Maintains: Outperform | $30 → $23 | $11.52 | +99.65% | 6 | Feb 7, 2025 | |
| IRTC iRhythm Technologies | Maintains: Outperform | $105 → $120 | $105.00 | +14.29% | 5 | Jan 8, 2025 | |
| TMDX TransMedics Group | Maintains: Outperform | $125 | $68.58 | +82.27% | 9 | Dec 3, 2024 | |
| AORT Artivion | Maintains: Outperform | $30 → $32 | $24.25 | +31.96% | 3 | Nov 8, 2024 | |
| LMAT LeMaitre Vascular | Reiterates: Outperform | $90 → $93 | $83.05 | +11.98% | 2 | Nov 1, 2024 | |
| ABT Abbott Laboratories | Initiates: Outperform | $130 | $130.82 | -0.63% | 1 | Oct 8, 2024 | |
| TLSI TriSalus Life Sciences | Initiates: Outperform | $10 | $5.62 | +77.94% | 1 | Sep 16, 2024 | |
| EW Edwards Lifesciences | Maintains: Outperform | $90 | $70.91 | +26.92% | 5 | Sep 12, 2024 | |
| NYXH Nyxoah | Maintains: Outperform | $15 → $13 | $7.65 | +69.93% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $135 | $116.95 | +15.43% | 1 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $219.94 | - | 6 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $5.84 | - | 8 | Feb 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $13.00 | +130.77% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.27 | +3,575.12% | 1 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $97 | $80.01 | +21.23% | 1 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $25.96 | +7.86% | 4 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4.5 | $2.37 | +89.87% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $1.96 | +716.33% | 1 | Sep 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $491.84 | - | 3 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $660 | $2.75 | +23,900.00% | 2 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $157.24 | - | 2 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $5.23 | - | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $100 | $33.75 | +196.30% | 1 | Jun 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $67.74 | - | 5 | Sep 12, 2018 |
AtriCure
Feb 13, 2025
Maintains: Outperform
Price Target: $36 → $45
Current: $31.83
Upside: +41.38%
Varex Imaging
Feb 7, 2025
Maintains: Outperform
Price Target: $30 → $23
Current: $11.52
Upside: +99.65%
iRhythm Technologies
Jan 8, 2025
Maintains: Outperform
Price Target: $105 → $120
Current: $105.00
Upside: +14.29%
TransMedics Group
Dec 3, 2024
Maintains: Outperform
Price Target: $125
Current: $68.58
Upside: +82.27%
Artivion
Nov 8, 2024
Maintains: Outperform
Price Target: $30 → $32
Current: $24.25
Upside: +31.96%
LeMaitre Vascular
Nov 1, 2024
Reiterates: Outperform
Price Target: $90 → $93
Current: $83.05
Upside: +11.98%
Abbott Laboratories
Oct 8, 2024
Initiates: Outperform
Price Target: $130
Current: $130.82
Upside: -0.63%
TriSalus Life Sciences
Sep 16, 2024
Initiates: Outperform
Price Target: $10
Current: $5.62
Upside: +77.94%
Edwards Lifesciences
Sep 12, 2024
Maintains: Outperform
Price Target: $90
Current: $70.91
Upside: +26.92%
Nyxoah
Aug 7, 2024
Maintains: Outperform
Price Target: $15 → $13
Current: $7.65
Upside: +69.93%
Jul 16, 2024
Initiates: Outperform
Price Target: $135
Current: $116.95
Upside: +15.43%
Jun 25, 2024
Downgrades: Perform
Price Target: n/a
Current: $219.94
Upside: -
Feb 22, 2024
Downgrades: Perform
Price Target: n/a
Current: $5.84
Upside: -
Aug 8, 2023
Maintains: Outperform
Price Target: $24 → $30
Current: $13.00
Upside: +130.77%
Jun 23, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.27
Upside: +3,575.12%
May 16, 2023
Initiates: Outperform
Price Target: $97
Current: $80.01
Upside: +21.23%
Mar 6, 2023
Reiterates: Outperform
Price Target: $28
Current: $25.96
Upside: +7.86%
Nov 29, 2022
Initiates: Outperform
Price Target: $4.5
Current: $2.37
Upside: +89.87%
Sep 24, 2021
Initiates: Outperform
Price Target: $16
Current: $1.96
Upside: +716.33%
Apr 21, 2021
Upgrades: Perform
Price Target: n/a
Current: $491.84
Upside: -
Nov 17, 2020
Upgrades: Outperform
Price Target: $660
Current: $2.75
Upside: +23,900.00%
Nov 3, 2020
Upgrades: Perform
Price Target: n/a
Current: $157.24
Upside: -
Sep 15, 2020
Initiates: Perform
Price Target: n/a
Current: $5.23
Upside: -
Jun 24, 2020
Initiates: Outperform
Price Target: $100
Current: $33.75
Upside: +196.30%
Sep 12, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $67.74
Upside: -